GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (OSTO:AZN) » Definitions » E10

AstraZeneca (OSTO:AZN) E10 : kr27.12 (As of Sep. 2024)


View and export this data going back to 1999. Start your Free Trial

What is AstraZeneca E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

AstraZeneca's adjusted earnings per share data for the three months ended in Sep. 2024 was kr9.308. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr27.12 for the trailing ten years ended in Sep. 2024.

During the past 12 months, AstraZeneca's average E10 Growth Rate was 18.30% per year. During the past 3 years, the average E10 Growth Rate was -5.10% per year. During the past 5 years, the average E10 Growth Rate was -9.00% per year. During the past 10 years, the average E10 Growth Rate was -8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of AstraZeneca was 77.50% per year. The lowest was -26.20% per year. And the median was 0.50% per year.

As of today (2024-12-14), AstraZeneca's current stock price is kr1458.50. AstraZeneca's E10 for the quarter that ended in Sep. 2024 was kr27.12. AstraZeneca's Shiller PE Ratio of today is 53.78.

During the past 13 years, the highest Shiller PE Ratio of AstraZeneca was 75.22. The lowest was 14.26. And the median was 32.99.


AstraZeneca E10 Historical Data

The historical data trend for AstraZeneca's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca E10 Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.67 23.53 20.21 19.77 22.73

AstraZeneca Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.70 22.73 25.44 26.08 27.12

Competitive Comparison of AstraZeneca's E10

For the Drug Manufacturers - General subindustry, AstraZeneca's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Shiller PE Ratio falls into.



AstraZeneca E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=9.308/133.5000*133.5000
=9.308

Current CPI (Sep. 2024) = 133.5000.

AstraZeneca Quarterly Data

per share eps CPI Adj_EPS
201412 -1.907 99.900 -2.548
201503 3.760 99.600 5.040
201506 4.546 100.100 6.063
201509 5.020 100.200 6.688
201512 5.351 100.400 7.115
201603 4.253 100.400 5.655
201606 -0.020 101.000 -0.026
201609 6.825 101.500 8.977
201612 13.350 102.200 17.439
201703 3.744 102.700 4.867
201706 3.298 103.500 4.254
201709 4.325 104.300 5.536
201712 8.644 105.000 10.990
201803 2.225 105.100 2.826
201806 2.376 105.900 2.995
201809 3.039 106.600 3.806
201812 7.405 107.100 9.230
201903 4.368 107.000 5.450
201906 0.847 107.900 1.048
201909 2.233 108.400 2.750
201912 2.264 108.500 2.786
202003 5.808 108.600 7.140
202006 5.400 108.800 6.626
202009 4.339 109.200 5.305
202012 6.523 109.400 7.960
202103 10.081 109.700 12.268
202106 3.527 111.400 4.227
202109 -9.508 112.400 -11.293
202112 -2.000 114.700 -2.328
202203 2.391 116.500 2.740
202206 2.308 120.500 2.557
202209 11.456 122.300 12.505
202212 6.019 125.300 6.413
202303 12.153 126.800 12.795
202306 12.600 129.400 12.999
202309 9.755 130.100 10.010
202312 6.360 130.500 6.506
202403 14.576 131.600 14.786
202406 13.004 133.000 13.053
202409 9.308 133.500 9.308

Add all the adjusted EPS together and divide 10 will get our e10.


AstraZeneca  (OSTO:AZN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AstraZeneca's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=1458.50/27.12
=53.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of AstraZeneca was 75.22. The lowest was 14.26. And the median was 32.99.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


AstraZeneca E10 Related Terms

Thank you for viewing the detailed overview of AstraZeneca's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.